Vaxart, Inc.(VXRT)Earnings, Financials & Key RatiosVaxart, Inc. (VXRT) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's reliance on non-recurring revenue is underscored by an OCF/NI ratio that fluctuated to -0.40 in 2026Q1, indicating that reported earnings are not supported by sustainable cash-generating activities.
Vaxart, Inc. (VXRT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Vaxart, Inc. (VXRT) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.02vs $0.21+109.5% | $39Mvs $51M-22.3% |
| Q2 2026 | Mar 12, 2026 | $0.24vs $0.08+400.0% | $104Mvs $36M+190.0% |
| Q4 2025 | Nov 13, 2025 | $0.04vs $0.07+42.9% | $72Mvs $36M+101.4% |
| Q3 2025 | Aug 13, 2025 | $0.07vs $0.09+22.2% | $40Mvs $2M+1705.9% |
Recent stock market news and headlines for Vaxart, Inc. (VXRT)
No vaccine-related serious adverse events (SAEs) or sustained Grade 3 or higher adverse events related to the vaccine reported
Company to Appoint Mutually Agreed Upon Independent Director; Forms Stockholder Engagement and Clinical and Regulatory Affairs Committees
Details Strategic Actions Taken by the Board to Advance the Company's Pipeline and Drive Value Creation Vaxart's Purpose-Built Board Brings the Proven Expertise Needed to Oversee its Next Phase of Growth Dissident Nominees Lack Relevant Clinical-Stage Biotech Expertise, Misrepresented Their Qualifications and Offered No Credible Ideas for Value Creation Vaxart Has Made Multiple Settlement Offers to the Dissident Shareholder Group – Daniel Houle Insists on Making This Proxy Contest About Winning a Seat for Himself Visit Vote.Vaxart.com for Additional Information and Voting Resources SOUTH SAN FRANCISCO, Calif., June 26, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform, today published a presentation urging shareholders to vote “FOR” ALL six of the Company's highly qualified director nominees on the WHITE proxy card in connection with its upcoming Annual Meeting of Stockholders scheduled to be held on July 16, 2026.
Latest Modification is Important Required Step to Releasing 12-month Data from 400-participant Sentinel Cohort Funding to Advance Data Analysis from More Than 5,000 Trial Participants Ahead of Key Trial Results SOUTH SAN FRANCISCO, Calif., June 25, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral vaccines based on its proprietary delivery platform, today announced that it has entered into a contract modification that releases additional funding from BARDA, through a contract with Advanced Technology International (“ATI”), to support continuation of the Company's ongoing Phase 2b COVID-19 oral pill vaccine candidate and advance the next phase of data analysis.
Urges Stockholders to Vote “FOR” ALL Six of Vaxart's Director Nominees on the WHITE Proxy Card TODAY Visit Vote.Vaxart.com for Additional Information and Voting Resources SOUTH SAN FRANCISCO, Calif., June 16, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform, today mailed a letter to shareholders from the Board's two newest independent directors, James Breitmeyer, M.D.
Key metrics vs top competitors for Vaxart, Inc. (VXRT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.55 | $133.16M | 7.86 | 726.68% | 6.88% | 22.26% | — | |
| $9.46 | $1.56B | 3.72 | 64.69% | -14.73% | — | — | |
| $8.76 | $9.17B | -23.05 | 668.31% | -606.15% | — | — | |
| $2.71 | $3.03M | -0.08 | -84.1% | -6753.69% | -164.92% | — | |
| $1.50 | $507.78M | -6.52 | 8.83% | -1605.22% | -127987.5% | — | |
| $1.06 | $38.63M | -4.61 | -64.74% | -245.12% | -1004.96% | — |
Vaxart, Inc. (VXRT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Vaxart, Inc. (VXRT) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 19, 2026·SEC
May 7, 2026·SEC
Apr 23, 2026·SEC
Get notified when VXRT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Vaxart, Inc. (VXRT) stock FAQ — growth, dividends, profitability & financials explained
Vaxart, Inc. (VXRT) reported $255.6M in revenue for fiscal year 2025. This represents a 7% increase from $239.9M in 1996.
Vaxart, Inc. (VXRT) grew revenue by 726.7% over the past year. This is strong growth.
Yes, Vaxart, Inc. (VXRT) is profitable, generating $37.1M in net income for fiscal year 2025 (6.9% net margin).
Vaxart, Inc. (VXRT) has a return on equity (ROE) of 22.3%. This is excellent, indicating efficient use of shareholder capital.
Vaxart, Inc. (VXRT) generated $14.8M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
